Makers Laboratories Reports Q3 FY25 Results, Revenue at ₹2,784.51 Lakhs

Mumbai, January 29, 2025 – Makers Laboratories Ltd. (BSE: 506919) has announced its unaudited financial results for the third quarter and nine months ended December 31, 2024. The company reported a revenue of ₹2,784.51 lakhs, reflecting a year-on-year growth compared to ₹2,569.98 lakhs in Q3 FY24.

Key Financial Highlights (Q3 FY25 - Consolidated)​

• Revenue from Operations: ₹2,784.51 lakhs (vs. ₹2,569.98 lakhs in Q3 FY24).
• Total Income: ₹2,958.77 lakhs (vs. ₹2,743.49 lakhs in Q3 FY24).
• EBITDA: ₹1,107.35 lakhs.
• Profit Before Tax (PBT): ₹1,207.35 lakhs.
• Net Profit (PAT): ₹1,870.70 lakhs, up 20.4% YoY.
• Basic EPS: ₹8.50 per share (vs. ₹5.73 in Q3 FY24).
• Diluted EPS: ₹8.50 per share (vs. ₹5.69 in Q3 FY24).

Segment Performance​

• Pharmaceuticals Revenue: ₹1,802.22 lakhs.
• Chemical Manufacturing Revenue: ₹982.29 lakhs.
• Total Segment Revenue: ₹2,784.51 lakhs.

Other Highlights​

• Profit from Sale of Property, Plant & Equipment: ₹1,010.00 lakhs.
• Net Cash Balance: ₹14,286 lakhs, reflecting high cash conversion.
• EBITDA Margin: 21.1%, up from 20.6% in Q3 FY24.
• DSO (Days Sales Outstanding): 42 days.

Regulatory Compliance & Corporate Development​

The Audit Committee and Board of Directors reviewed and approved the financial results on January 29, 2025. The Statutory Auditors have issued an unqualified review report.

Market Outlook & Strategic Positioning​

Makers Laboratories continues to grow in the pharmaceutical and chemical manufacturing segments, leveraging cost optimization and operational efficiencies to enhance profitability.